Advertisement

CanSino's covax to continue advancing phase-3 trials

Follow The Hawk on Google News+ Follow

Advertisement


Beijing: China's CanSino Biologics Inc. has got green light to continue phase-3 trials of its Covid-19 vaccine with the support of findings of an independent data monitoring committee, said media reports.

The independent committee "found the drugmaker's Covid-19 vaccine met its pre-specified primary safety and efficacy targets under an interim analysis of phase-3 trial data," the report said.

Advertisement

No adverse events related to the vaccine had occurred, according to the Xinhua news agency.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

The vaccine candidate, referred to as Ad5-nCoV, is developed by CanSino Biologics Inc. and the Academy of Military Sciences in China.

CanSino was approved to conduct phase-3 clinical trials in some countries in Europe and Asia, Wu Yuanbin, an official with China's Ministry of Science and Technology, said in September last year.

--IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST